Hemofagocitose em cultura de sangue periférico precedendo hemofagocitose em biópsia de medula óssea na síndrome hemofagocítica secundária / Hemophagocytosis in peripheral blood culture preceding hemophagocytosis in bone marrow biopsy in secondary hemophagocytic syndrome

A síndrome hemofagocítica é determinada por desregulação do sistema imunológico, caracterizada por ativação excessiva de macrófagos, resultando em fagocitose de células sanguíneas normais no fígado, baço e medula óssea. Pode ser primária (genética) ou secundária (adquirida). Em adultos quase sempre é secundária, tendo infecções, neoplasias e doenças autoimunes como frequentes desencadeadores. Entre as principais manifestações da síndrome estão febre prolongada e hepatoesplenomegalia. O diagnóstico até o momento é confirmado pelo achado de hemofagocitose em biópsia de medula óssea. Entretanto, é descrito que a biópsia de medula óssea é normal nos primeiros dias de manifestações da síndrome. O presente relato tem como objetivo mostrar a observação de hemofagocitose em cultura de células de sangue periférico de paciente de 29 anos precedendo a hemofagocitose em biópsia de medula óssea. A paciente apresentava diferentes infecções, com grave comprometimento do estado geral e sem melhora com o tratamento das infecções. O achado laboratorial permitiu o tratamento precoce da síndrome hemofagocítica e a melhora da paciente. No presente relato a técnica utilizada está descrita detalhadamente para que possa ser reproduzida, além de ser apresentada uma revisão não sistemática da literatura sobre a síndrome.

Hemophagocytic syndrome, which is caused by dysregulation of the immune system, is characterized by excessive macrophage activation, resulting in phagocytosis of normal blood cells in the liver, spleen, and bone marrow. It can be primary (genetic) or secondary (acquired). In adults, it is almost always secondary, with infections, neoplasms, and autoimmune diseases as frequent triggers. The main manifestations of this syndrome are prolonged fever and hepatosplenomegaly. Currently, diagnosis is confirmed through finding hemophagocytosis in a bone marrow biopsy. However, it has been reported that bone marrow biopsy results are still normal on the first day the syndrome manifests. Here we report observing hemophagocytosis in cultured peripheral blood cells from a 29-year-old patient prior to finding hemophagocytosis in bone marrow biopsy. The patient had various infections and a poor general condition, which did not improve after treating the infections. The laboratory findings allowed early treatment of hemophagocytic syndrome and the patient improved. We describe our technique in detail so it can be reproduced, and we provide a non-systematic review of the literature on the syndrome.

Hemophagocytic lymphohistiocytosis: presentation and outcome of twenty-one patients at a single institution

ABSTRACT Introduction: Hemophagocytic lymphohistiocytosis comprises a systemic hyperactivation of macrophages that requires prompt recognition of symptoms and early treatment. Objective and Method: In this context, we described clinical and laboratory characteristics, therapeutic modality and outcome of 21 patients with HLH treated at a pediatric oncology hospital between January 2000 and February 2019. Results: HLH mainly affected females, fever was the most frequent clinical sign and hyperferritinemia was the most prevalent laboratory abnormality. All patients were admitted to the intensive care unit (ICU) at some point. Fifteen (71.4%) patients presented resolution criteria and eight (53.3%) of them presented reactivation. The mortality rate was 57.1% and the mean time between diagnosis and death was 9.98 months. The 5-year overall survival (OS) was 36.7%. We observed a significant difference in prognosis associated with reactivation of HLH. These patients demonstrated an estimated 5-year OS of 25%, while all patients that did not reactivate were alive until the end of the follow-up. Conclusion: In conclusion, HLH is a rare disease with a high mortality rate, especially in patients with disease reactivation and those with familial- or immunodeficiency-associated forms, which makes early recognition and genetic testing crucial for appropriate management and prompt SCT indication.

Perfil dos pacientes com hiperferritinemia em acompanhamento ambulatorial em um serviço no sul do Brasil / Profile of patients with hyperferritinemia in ambulatorial follow-up in southern Brazil

O achado de hiperferritinemia é comum na prática clínica. Além de representar os estoques de ferro no organismo, a ferritina se mostra como proteína de fase inflamatória, podendo elevar-se em comorbidades inflamatórias agudas ou crônicas e se associar com a chamada síndrome plurimetabólica. Objetivo: Avaliar as características clínicas de pacientes com hiperferritinemia em acompanhamento ambulatorial no período de janeiro de 2013 a novembro de 2016. Métodos: Estudo observacional transversal, desenvolvido em um serviço de Hematologia na cidade de Tubarão, Santa Catarina. Coletaram-se dados de 136 pacientes com o diagnóstico de hiperferritinemia através de prontuários digitais. Foram realizadas análises descritivas e associações com os testes qui-quadrado e t Student, quando apropriado. Resultados: Houve um predomínio do sexo masculino (83,50%) com idade média de 56,62 anos, a média de ferritina de 693,45mcg/L e de ferro sérico 121,52mcg/dL, sendo as causas secundárias de hiperferritinemia as predominantes. Ao se estratificar os valores de ferritina constatou-se que os pacientes com ferritina >1000mcg/L tiveram um risco 50% maior de possuir alterações ao ultrassom, 70% maior prevalência de HDL<40 e 40% maior prevalência de hipertrigliceridemia. Os pacientes com ferritina >400mcg/L tiveram duas vezes maior chance de apresentar resistência à insulina. Conclusão: As principais causas de hiperferritinemia foram secundárias a doenças crônicas metabólicas

Hyperferritinemia is common in the clinical practice. In aside from representing the stocks of iron in the organism, ferritin is also a inflammatory phase protein, witch can be elevated in chronic or acute inflammatory comorbidities and be associated with plurimetabolic syndrome. This study aims the evaluation of the clinical characteristics of ambulatory patients with hyperferritinemia between January-2013 and November-2016. Methods: It is a cross-sectional, descriptive study, developed in the hematology center of the medical specialities clinic in Tubarão ­ Santa Catarina. Data from 136 patients have been collected and then transferred to an Excel spreadsheet, imported to Epiiinfo 7 and the expressed into absolute and relative numbers, graphics and figures. Results: It was found a predominance of males (83,50%) with a mean age of 56,62 years, a mean ferritin level of 693,45mcg/L and seric iron of 121,52mcg/dL being the secondary causes of hyperferritinemia the most predominant. When stratified the ferritin levels, it was verified that patients with a ferritin >1000mcg/L had 50% more risk of having ultrasound alterations, 70% more prevalence of HDL<40 and 40% more prevalence of having hypertriglyceridemia. Patients with a ferrintin >400mcg/L had twice as many chances of having insulin resistance. Conclusion: The main causes of hyperferritinemia were secondary to chronic metabolic diseases

Brazilian family with hyperferritinemia-cataract syndrome: case report

ABSTRACT Hereditary hyperferritinemia-cataract syndrome is a rare autosomal dominant disease caused by a genetic mutation in the iron responsive element in the 5' untranslated region of the ferritin light chain gene. Hereditary hyperferritinemia-cataract syndrome is characterized by elevated serum ferritin levels and bilateral cataract development early in life and may be misdiagnosed as hemochromatosis. This case report describes a Brazilian family with a clinical diagnosis of hereditary hyperferritinemia-cataract syndrome, which was submitted to ferritin light chain gene sequencing. The genetic mutation c.-164C>G was identified in the 5' untranslated region. In conclusion, genetic testing can be used for accurate diagnosis of hereditary hyperferritinemia-cataract syndrome to avoid misdiagnosis of hemochromatosis, other diseases associated with iron overload or ophthalmic diseases.

Relationship between marked hyperferritinemia and hemophagocytic lymphohistiocytosis / 北京大学学报(医学版)

OBJECTIVE@#To investigate the relationship between marked hyperferritinemia (MHF) and hemophagocytic lymphohistiocytosis(HLH).@*METHODS@#The clinical data of 123 patients with MHF admitted to Peking University People's Hospital from January 2017 to September 2018 were collected, including demographics, baseline characteristics, signs and symptoms, blood routine, blood biochemistry, coagulation function parameters, such as prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (Fib), d-dimer (D-D), fibrin degradation product (FDP), blood ferritin, natural killer (NK) cell activity, soluble interleukin (IL)-2 receptor and bone marrow examination. According to the diagnosis of HLH, the patients were divided into HLH group and non HLH group. The patients were divided into death group and survival group according to the 3-month follow-up results. The groups were compared and statistically analyzed.@*RESULTS@#In the 123 patients with MHF, the average age was (44.2±17.4) years with a male/female ratio of 1.3 ∶1. The most common causes were hematolo-gic malignancies, rheumatologic and inflammatory disorders, iron overload, and HLH. HLH was enriched as the ferritin increased, and the HLH ratios were 28.8%, 40.0%, 54.5%, 50.0%, 50.0% in ferritin value of 10 000-19 999, 20 000-29 999, 30 000-39 999, 40 000-49 999 μg/L, more than 50 000 μg/L respectively. There were 46 cases of HLH, among which 15 cases were secondary to malignancies, 14 cases secondary to rheumatologic disorders, 2 cases secondary to infection, and 15 cases with no clear precipitating cause. There were significant differences between the HLH group and non-HLH group in hepatomegaly, splenomegaly, lymphadenectasis, albumin (ALB), fibrinogen(Fib), P < 0.05, and no significant differences in age, gender, fever, disturbance of consciousness, ferritin level on presentation, maximum ferritin level, cytopenia in 2 or more cell lines, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), direct bilirubin (DBIL), triglyceride (TG), coagulation parameters (PT, APTT, D-D, FDP, exception of Fib), and mortality rate (P > 0.05). There were significant differences between the death group and survival group in disturbance of consciousness, platelet count, PT, TBIL, and DBIL (P < 0.05), but no significant differences in age, gender, fever, hepatomegaly, splenomegaly, lymphadenectasis, ferritin level on presentation, maximum ferritin level, neutrophils, hemoglobin, ALT, AST, ALB, TG, coagulation parameters (Fib, APTT, D-D, FDP, exception of PT) and the HLH ratio (P > 0.05).@*CONCLUSION@#HLH was enriched as the ferritin increased, but marked hyperferritinemia was not specific for HLH in adults.

Comparative study of serum ferritin levels and hepatic transaminases between uncomplicated paediatric dengue inpatients and other febrile illnesses in Kanchipuram, India

Background: Fever is the most common complaint with bringing children for hospital consultation. Dengue is a cause of public health concern with case fatality rate of 1%. Ferritin is an acute-phase reactant which is produced in response to infection and inflammation. Liver enzymes are also considered as markers of febrile illness. Aim of this study was to assess serum ferritin levels, aspartate-aminotransferase (AST) and alanine-aminotransferase (ALT) levels in pediatric inpatients with febrile illness, to correlate it with patient’s Dengue profile and to analyse these parameters with sub-group analysis of dengue and OFI.Methods: Among 120 children admitted for fever of more than 3 days duration were included in the study. 58 were Dengue-NS1 positive and the remaining 62 were considered to be OFI. Serum ferritin levels, AST and ALT were the investigative parameters measured at the time of admission for the study and treated as per WHO Dengue Guidelines. Data was coded and entered in Microsoft Excel 2013. Data was analysed using SPSS v16. p value of <0.05 was considered statistically significant.Results: Ferritin levels were higher in Dengue-IgM positive subgroup than in OFI subgroup (U= 173, Z score -6.09, p<0.00001). AST levels are higher in Dengue-NS1 positive subgroup than in OFI subgroup (U= 103, Z score -8.08, p<0.00001). AST levels were also higher in Dengue-IgM positive subgroup than in OFI subgroup (U= 377.5, Z score -4.86, p<0.00001). ALT levels are higher in Dengue-NS1 positive subgroup than in OFI subgroup (U=76, Z score -8.95, p<0.00001) as well as in Dengue-IgM positive subgroup than in OFI subgroup (U= 417, Z score -4.4, p<0.00001).Conclusions: Hyperferritinemia and elevation of hepatic-transaminases is seen in dengue. Although elevated in other febrile illnesses, it is elevated more so in dengue. This can be a predictor of severity of dengue fever, but needs to be confirmed in larger studies.

Causes of Hyperferritinemia and Red Blood Cell Transfusion / 대한수혈학회지

BACKGROUND: Ferritin is used to detect iron overload in patients with chronic red blood cell transfusions. Although ferritin reflects the amount of iron storage in the body, it may increase nonspecifically in inflammation and infection. This study analyzed the cause of increased ferritin and the association with a red blood cell (RBC) transfusion. METHODS: The medical records of patients who visited the authors' hospital from January to December 2017 and underwent a ferritin test were reviewed retrospectively. Hyperferritinemia was defined as a ferritin level more than 1,000 ng/mL. The causes of hyperferritinemia were investigated by examining the laboratory findings and medical records. RESULTS: The results revealed 417 cases of hyperferritinemia in 238 patients during the period. The most common diseases were hematologic malignancies from 125 cases (30.0%) in 31 patients and infectious diseases were the second most common. Iron overload was suspected in 119 cases in 33 patients, and 12 patients (76 cases) were transfused with more than 8 units of RBC for 1 year before the test. CONCLUSION: In hyperferritinemia, the rate of iron overload is high considering the underlying diseases and chronic RBC transfusion. To determine iron storage status accurately, it will be helpful to measure the C-reactive protein (CRP) and iron saturation in the ferritin test. Careful attention should be paid to habitual iron formulations and frequent transfusions due to the possibility of iron overload.

Hyperferritinemia in patients with nonalcoholic fatty liver disease / Hiperferritinemia em pacientes com doença hepática gordurosa não alcoólica

Summary Objective: In liver diseases, hyperferritinemia (HYF) is related to injured cells in acquired and genetic conditions with or without iron overload. It is frequent in patients with nonalcoholic fatty liver disease (NAFLD), in which it is necessary to define the mean of HYF to establish the better approach for them. The present study evaluated the significance of elevated ferritin in patients with NAFLD and steatohepatitis (NASH). Method: The review was performed using search instruments of indexed scientific material, including MEDLINE (by PubMed), Web of Science, IBECS and LILACS, to identify articles published in Portuguese, English and Spanish, from 2005 to May, 2016. Studies eligible included place and year of publication, diagnose criteria to NAFLD, specifications of serum ferritin measurements and/or liver histopathologic study. Exclusion criteria included studies with patients with alcohol consumption ≥ 20 g/day and other liver diseases. Results: A total of 11 from 30 articles were selected. It included 3,564 patients and they were cross-sectional, retrospective, case series and case-control. The result's analyses showed in 10 of these studies a relationship between ferritin elevated serum levels and NAFLD/NASH with and without fibrosis and insulin resistance. Conclusion: Hyperferritinemia in patients with NAFLD/NASH is associated more frequently with hepatocellular injury than hemochromatosis. These data suggest the relevance to evaluate carefully HYF in patients with NAFLD/NASH to establish appropriate clinical approach.

Resumo Objetivo: A hiperferritinemia (HPF) está associada à agressão hepatocelular nas doenças do fígado e à sobrecarga de ferro, em doenças genéticas e adquiridas. A HPF é frequente em pacientes com doença hepática gordurosa não alcoólica (DHGNA) e é necessário definir seu significado para estabelecer as melhores condutas para esses indivíduos. Esta revisão avaliou o significado da HPF em portadores de DHGNA e esteato-hepatite não alcoólica (EHNA). Método: A busca de artigos foi realizada através do PubMed (Medline), Web of Science e Lilacs, e foram selecionados aqueles publicados em português, inglês e espanhol de 2005 a maio de 2016. Os artigos foram elegíveis quando informavam data e local da publicação, critérios diagnósticos para DHGNA, especificações das dosagens de ferritina sérica e/ou estudo histopatológico. Foram excluídos os artigos cujos pacientes relataram ingestão alcoólica ≥ 20 g/dia ou eram portadores de outras doenças do fígado. Resultados: Foram selecionados 11 de 30 artigos, totalizando 3.564 pacientes. Os artigos eram de corte transversal, retrospectivos, série de casos e caso-controles. Em dez artigos, observou-se correlação entre alteração de ferritina e DHGNA/EHNA com e sem fibrose hepática e resistência à insulina. Conclusão: Hiperferritinemia em pacientes com DHGNA/EHNA se associa com maior frequência à agressão hepatocelular do que com sobrecarga de ferro hepático. Os resultados da revisão sugerem a necessidade de um maior cuidado na interpretação da elevação da ferritina sérica em pacientes com DHGNA/EHNA para o estabelecimento de condutas clínicas apropriadas.

Estudio del paciente con hiperferritinemia / Study of the patient with hyperferritinemia

Resumen: la hiperferritinemia, definida por ferritina sérica mayor de 200 µg/L en mujeres y de 300 µg/L en hombres, representa un reto para el clínico. De acuerdo con la etiología, la hiperferritinemia se puede subdividir en tres grupos: el primero correspondiente a la causada por enfermedades frecuentemente asociadas, como el síndrome metabólico, la hepatopatía alcohólica, la hepatopatía no alcohólica y procesos inflamatorios incluidas infecciones, enfermedades inflamatorias crónicas, enfermedades autoinmunes y algunos procesos malignos; el segundo, correspondiente a la causada por enfermedades poco frecuentemente asociadas, como la hemocromatosis hereditaria, algunas enfermedades hematológicas con anemia y la terapia transfusional permanente; y un tercer grupo, correspondiente a la causada por enfermedades raramente asociadas, como el síndrome hereditario de hiperferritinemia y cataratas, la aceruloplasminemia, la atransferrinemia o hipotransferrinemia, la porfiria cutánea tarda, la hemocromatosis neonatal, la sobrecarga de hierro africana y la enfermedad de Gaucher. El aspecto clínico más importante es definir, mediante la clínica y estudios simples y especializados, la causa asociada a la hiperferritinemia e intervenirla como punto de partida para su manejo. Desde el punto de vista del paciente es importante realizar estudios de ferrocinética (ferritina sérica y saturación de transferrina) y medición de sobrecarga de hierro en órganos blanco, mediante resonancia magnética, la cual presenta alta sensibilidad y especificidad. Todo esto significa la aplicación de algoritmos de manejo y seguimiento del paciente con hiperferritinemia. El manejo del síndrome depende de la etiología con la cual está asociada y la ausencia o presencia de sobrecarga de hierro, siendo, exclusivamente en este último caso, la flebotomía la mejor opción. (AU)

µg/L in men, represents a challenge for the clinician. Based on the etiology, hyperferritinemia can be subdivided into three groups: the first corresponds to the caused by diseases frequently associated, including the metabolic syndrome, alcoholic liver disease, non-alcoholic liver disease and inflammatory processes (infections, chronic inflammatory diseases, autoimmune diseases, and some malignant processes); the second corresponds to the initiated by diseases associated in low frequency, which include hereditary hemochromatosis, some hematological diseases characterized by anemia and of permanent transfusional therapies; and a third group corresponding to the induced by diseases rarely associated, among which are the hereditary syndrome of hyperferritinemia and cataracts, the aceruloplasminemia, the atransferrinemia or hypotransferrinemia, the cutaneous porphyria tarda, the neonatal hemochromatosis, the overload of African iron, the Gaucher disease. The most important clinical aspect is to define, through clinical findings and simple and specialized studies, the associated cause of hyperferritinemia and intervene it as starting point of the management. From the patient's point of view it is vital to perform ferrokinetic studies; in particular serum ferritin and transferrin saturation, and iron overload measurement in white organs through magnetic resonance, which presents high sensitivity and specificity. All this means the application of algorithms of handling and monitoring of the patient with hyperferritinemia. The management of the syndrome depends on the associated etiology and the absence or presence of iron overload; being, exclusively in this last case, the phlebotomy the best option. (AU)

Infection associated haemophagocytic syndrome in severe dengue infection – a case series in a district hospital

Haemophagocytic lymphohistiocytosis (HLH) is a potentially fatal disorder resulting from uncontrolled hyperinflammatory response. There had been increase in cases of one of the secondary form of HLH, i.e., infectionassociated haemophagocytic syndrome (IAHS) in severe dengue in recent years. However, the condition remains under diagnosed due to lack of awareness compounded by the lack of validated diagnostic criteria. Severe hepatitis with prolonged cytopenias, severe hyperferritinemia, hypofibrinogenemia and persistent fever were evident in all four cases reported. All the subjects survived with supportive care and adjuvant steroid therapy. Prospective controlled studies are needed to develop diagnostic criteria and management protocol for IAHS in severe dengue.

Hyperferritinemia in Hereditary Spherocytosis: A Diagnostic Challenge.

Aims: Hereditary spherocytosis is an autosomal dominant disorder characterized by increased red blood cell osmotic fragility and impaired deformability. Hereditary hemochromatosis is an autosomal recessive disorder of iron metabolism which results in damage to multiple organs. Presentation of Case: This case describes a 42 year old Chinese male who presents with jaundice. He denies any fever, vomiting, anorexia or loss of weight. Urine and stool colour were normal. He had no history of blood transfusions or prolonged iron therapy. In addition, he had a past history of open cholecystectomy for recurrent acute cholecystitis. He had a family history of jaundice in which his father underwent a cholecystectomy and had multiple blood transfusions. On physical examination, he was jaundiced. His spleen was enlarged 6 cms from the left costal margin. The peripheral blood film showed mild anemia with increased reticulocyte response and spherocytosis suggestive of hereditary spherocytosis. Direct Coombs test was negative and there was an increase in red blood cell osmotic fragility. Iron studies revealed hyperferritinemia. Genetic testing showed homozygosity for the (hemochromatosis gene) HFE mutation C282Y. Ultrasonography of the abdomen revealed splenomegaly with no evidence of liver cirrhosis. He underwent regular venesections and his serum ferritin improved subsequently. Conclusion: Iron overload in a patient with non transfusional hereditary spherocytosis should prompt screening for HFE mutations and warrant early screening of family members to prevent serious complications.

Measurement of serum growth differentiation factor 15 concentration in children with hemophagocytic lympohistiocytosis and implications in the development of hyperferritinemia / 中华实用儿科临床杂志

Objective To measure the serum growth differentiation factor (GDF15) levels in children with hemophagocytic lympohistiocytosis (HLH),and to explore its possible implications in the development of hyperferritinemia in HLH.Methods Twenty-eight children with newly-diagnosed HLH and 20 age-and-sex matched healthy children were enrolled in this study as research subjects and controls respectively.Serum GDF15 levels were measured by Quantikine ELISA assay (product of R&D Company,USA) according to manufacturer's instructions.Serum ferritin concentration and other biochemical parameters were determined by conventional methods.Comparison of serum GDF15 levels between HLH group and healthy control group were made by nonparametric Mann-Whitney test.Correlations between serum GDF15 concentration and hemobiochemical parameters (Hb,serum ferritin,fibrinogen,blood lipids,and liver and renal function tests) were made via Spearman correlation analysis.Results Serum GDF15 concentration was significantly higher in HLH group than that in healthy control group,with median concentrations and ranges of 1710 ng/L,190-2400 ng/L,and 260 ng/L,104-649 ng/L,respectively (P ＜ 0.001).Serum GDF15 concentration was correlated neither to Hb concentration at diagnosis nor to lowest Hb concentration before HLH-directed chemotherapy.Nevertheless it was positively correlated to serum level of total bilirubin at diagnosis and highest concentration of triglycerates during disease course (x2 =0.475,0.465 ; P =0.011,0.019,respectively),and negatively correlated to lowest levels of fibrinogen and albumin at diagnosis (x2 =-0.423,-0.399 ;P =0.031,0.039,respectively).Serum GDF15 level was not correlated to underlying etiology and mortality rate of children with HLH.Conclusions GDF15 has been documented as an upstream negative regulator of hepcidin,the central iron regulatory hormone produced primarily by hepatocytes,and is massively produced by activated macrophages in an autocrine fashion to suppress further activation of macrophages.This research finding that serum GDF15 level is significantly elevated in children with HLH suggests that GDF 15 is intimately implicated in the modulation of iron homeostasis and the development of hyperferritinemia in HLH.

Hiperferritinemia como factor pronóstico de inmunosupresión en pacientes con síndrome de inmunodeficiencia adquirida / Hyperferritinemia as a prognostic factor for immnosuppression in patients with acquired immnodeficiency syndrome

Se realiza una investigación prospectiva con el objetivo de determinar si la hiperferritinemia es un factor pronóstico de inmunosupresión en pacientes con síndrome de inmunodeficiencia adquirida (SIDA). La población estuvo conformada por 40 pacientes hospitalizados en el Hospital Universitario de Maracaibo, durante los meses de Enero a Octubre del 2010. 27 (67,50%) pacientes fueron de sexo masculino y 13 (32,50%) femeninos. El 55,00% presentó hiperferritinemia. 22,50% presentaron contaje de linfocitos T CD4+ entre 200-400 cel/mm³ con un promedio de ferritina de 144,2 ± 127,1 ng/mL y, el 77,50% contaje de linfocitos T CD4+ < 200 cel/mm³ con un promedio de ferritina de 1100,0 ± 984,7 ng/mL (p = 0,01). Se demostró una correlación inversamente negativa entre niveles elevados de ferritina con niveles bajos de contaje de linfocitos T CD4+ (r = 0,3135, p = 0,030), cifras bajas de leucocitos (r= 0, 7458, p= 0,012), cifras bajas de proteínas (r= 0,5814, p= 0,01) y una relación directamente proporcional con el aumento de la VSG (r = 0,7422, p= 0,001). En los pacientes fallecidos el promedio de ferritina (1180,0 ± 1.072) estadísticamente (p= 0,018) fue más elevado en comparación con el promedio de ferritina (474 ±440,2) de los pacientes que sobrevivieron. Se concluye que se puede tomar en cuenta a la hiperferritinemia como factor pronóstico de inmunosupresión en pacientes con diagnóstico de SIDA

A prospective study was carried out to determine if hyperferritinemia is a predictive factor for immunosuppression in patients with acquired immunodeficiency syndrome (AIDS). The population consisted of 40 patients hospitalized at the University Hospital of Maracaibo (Hospital Universitario de Maracaibo), from January to October, 2010. Twenty-seven (67.50%) patients were male and 13 (32.50%) were female. 22.50% had a T CD4+ lymphocyte count between 200-400 cells/mm³ with a mean ferritin of 144.2 ± 127.1 ng/mL; 77.50% had a T CD4+ lymphocyte count of <200 cells/mm³ and a ferritin average of 1100.0 ± 984.7 ng/mL (p = 0.01). An inverse negative correlation was found between high ferritin levels and low T CD4+ lymphocyte count (r = 0.3135, p = 0.030), low numbers of leukocytes (r = 0, 7458 p = 0.012), low levels of protein (r = 0.5814, p = 0.01), and a directly proportional relation with the increase of ESR (r = 0.7422, p = 0.001). In patients who died, the mean ferritin level (1180.0 ± 1,072) statistically (p = 0.018) was higher compared with the average ferritin level (474 ± 440.2) of patients who survived. Conclusions are that these results are sufficiently relevant to take hyperferritinemia into account as a prognostic factor for the immunosuppression of diagnosed AIDS patients

Enfermedad de Still del adulto / Still's disease of adult

Se presenta un paciente del sexo masculino de 51 años de edad que fue hospitalizado por odinofagia, fiebre elevada, poliartritis, además de leucocitosis con neutrofilia y eritrosedimentación acelerada. Durante el ingreso se le constata poliserositis, neumonitis y miocarditis con insuficiencia cardiaca izquierda, hipertransaminasemia, hiperferritinemia y factor reumatoideo con anti DNA de doble cadena negativos. Se inició tratamiento con corticoesteroides e inmunosupresores (azatioprina). La respuesta no fue la esperada y hubo que cambiar el inmunosupresor por metotrexate. La poliartritis febril de evolución policíclica es la forma de presentación más frecuente de la enfermedad de Still del adulto. La hiperferritinemia mayor de 1 000 ng/mL es una herramienta útil para el diagnóstico y su normalización es indicador de éxito terapéutico. No existen manifestaciones clínicas, ni pruebas de laboratorio patognomónicas, por lo que el diagnóstico continúa siendo por exclusión

This is the case of man aged 51 admitted due to odynophagia, high fever, polyarthritis, as well as leukocytes with neutrophilia and accelerated erythrosedimentation. During admission it was noted polyserositis, pneumonitis and myocarditis with left cardiac insufficiency, hyper-transaminasemia, hyper-ferritinemia and rheumatoid factor with anti-AND of negative double-chain. Treatment was started with corticosteroids and immunosuppressive agents (azathioprine). Response was not the expected one and it was necessary to change the immunosuppressive agent by methotrexate. Febrile polyarthritis of polycyclic evolution is the more frequent presentation of the Still's disease in adult. Hyper-ferritinemia over 1 000 ng/mL is an useful tool for diagnosis and its normalization is an indicator of therapeutical success. There were neither clinical manifestations nor pathognomonic laboratory tests thus, diagnosis remains by exclusion

Síndrome de ativação macrofágica secundária à infecção aguda pelo vírus Epstein-Barr: [relato de caso] / Macrophage activation syndrome triggered by Epstein-Barr virus: [case report]

A síndrome de ativação macrofágica (SAM) ou síndrome hemofagocítica secundária (reativa) consiste de uma rara, grave e potencialmente fatal complicação das doenças reumáticas crônicas, particularmente da artrite idiopática juvenil de início sistêmico, doença de Still do adulto e lúpus eritematoso sistêmico. É caracterizada pela excessiva ativação dos macrófagos, resultando febre, hepatoesplenomegalia, linfadenomegalia, envolvimento neurológico, graus variáveis de citopenias, hiperferritinemia, distúrbio hepático, coagulação intravascular e freqüente falência de múltiplos órgãos. Também ocorre em associação com neoplasias, imunodeficiências e variedade de agentes infecciosos virais (sobretudo do grupo do herpes), bacterianos e fúngicos. Relatamos um caso de SAM decorrente de infecção viral aguda pelo vírus Epstein-Barr tratado com corticóide oral

The macrophage activation syndrome (MAS) or secondary haemophagocytic syndrome (reactive) is an uncommon, severe and life-threatening complication of chronic rheumatic diseases, especially systemic onset juvenile idiopathic arthritis, adult-onset Still disease and systemic lupus eritematosus. It is characterized by the excessive activation of macrophages, resulting in fever, hepatoesplenomegaly, lymphadenopathy, neurological involvement, variable cytopenias, hyperferritinemia, liver disease, intravascular coagulation, often resulting in fatal multiple organ failure. Besides chronic rheumatic diseases, it is also seen in a heterogeneous group of diseases like neoplasms, imunodeficiencies and viruses (especially the herpes group), bacteria and fungi infections. We describe a case report of one patient with MAS triggered by Epstein-Barr virus infection treated with oral corticosteroid.